Upregulation of drug transporter expression by osteopontin in prostate cancer cellss

Molecular Pharmacology

Volumn 83, Issue 5, 2013, Pages 968-977

  Hsieh, I Shan ^a   Huang, Wei Hsun ^a   Liou, Houng Chi ^a   Chuang, Woei Jer ^c   Yang, Rong Sen ^b   Fu, Wen Mei ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; OSTEOPONTIN; PACLITAXEL; RAPAMYCIN; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOFLUORESCENCE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL VIABILITY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPOXIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, INBRED NOD; MICE, SCID; OSTEOPONTIN; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876544010     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.082339     Document Type: Article

References (48)

1. Abu Ajaj K, Graeser R, and Kratz F (2012) Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin. Breast Cancer Res Treat 134:117-129.
2. Bodor M, Kelly EJ, and Ho RJ (2005) Characterization of the human MDR1 gene. AAPS J 7:E1-E5. (Pubitemid 41554190)
3. Bonfil RD, Chinni S, Fridman R, Kim HR, and Cher ML (2007) Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. Urol Oncol 25:407-411. (Pubitemid 47362762)
4. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, and Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12: 3337-3343.
5. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, and Dewhirst MW (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943. (Pubitemid 26065381)
6. Bussard KM, Gay CV, and Mastro AM (2008) The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 27:41-55.
7. Caruso DJ, Carmack AJ, Lokeshwar VB, Duncan RC, Soloway MS, and Lokeshwar BL (2008) Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res 14:4111-4118.
8. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, Rittling SR, Denhardt DT, and Hruska KA (2003) Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14: 173-189. (Pubitemid 36106028)
9. Denhardt DT and Guo X (1993) Osteopontin: A protein with diverse functions. FASEB J 7:1475-1482. (Pubitemid 24003267)
10. Denhardt DT and Noda M (1998) Osteopontin expression and function: Role in bone remodeling. J Cell Biochem Suppl 30-31:92-102. (Pubitemid 29028730)
11. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, and Schuetz JD, et al. (2002) Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974-981. (Pubitemid 34441761)
12. Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171. (Pubitemid 19172967)
13. Germann UA, Pastan I, and Gottesman MM (1993) P-glycoproteins: Mediators of multidrug resistance. Semin Cell Biol 4:63-76.
14. Gonda TA, Tu S, and Wang TC (2009) Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 8:2005-2013.
15. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627. (Pubitemid 34177898)
16. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58. (Pubitemid 37328807)
17. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, and Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91. (Pubitemid 26008141)
18. Graessmann M, Berg B, Fuchs B, Klein A, and Graessmann A (2007) Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 26:2840-2850. (Pubitemid 46701443)
19. Hotte SJ, Winquist EW, Stitt L, Wilson SM, and Chambers AF (2002) Plasma osteopontin: Associations with survival and metastasis to bone in men with hormonerefractory prostate carcinoma. Cancer 95:506-512. (Pubitemid 34810175)
20. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
21. Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, Pritchard C, Nelson PS, and Roy-Burman P (2006) Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66:883-888. (Pubitemid 43165954)
22. Kimbro KS and Simons JW (2006) Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13:739-749. (Pubitemid 44763255)
23. Kizaka-Kondoh S, Inoue M, Harada H, and Hiraoka M (2003) Tumor hypoxia: A target for selective cancer therapy. Cancer Sci 94:1021-1028. (Pubitemid 38035514)
24. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, and Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9: 59-67. (Pubitemid 36109716)
25. Leslie EM, Deeley RG, and Cole SP (2005) Multidrug resistance proteins: Role of Pglycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237. (Pubitemid 40552845)
26. Li Y, Li L, Wang JT, Kan X, and Lu JG (2012) Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol . 9:1429-1434.
27. Luedtke CC, McKee MD, Cyr DG, Gregory M, Kaartinen MT, Mui J, and Hermo L (2002) Osteopontin expression and regulation in the testis, efferent ducts, and epididymis of rats during postnatal development through to adulthood. Biol Reprod 66:1437-1448. (Pubitemid 34462288)
28. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Jr, Franklin WA, Le QT, Crowley JJ, and Gandara DR SWOG (2008) Lower osteopontin plasma levels are associated with superior outcomes in advanced non-smallcell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26:4771-4776.
29. Marquez B and Van Bambeke F (2011) ABC multidrug transporters: Target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets 12:600-620.
30. Meads MB, Gatenby RA, and Dalton WS (2009) Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat Rev Cancer 9: 665-674.
31. Moriyama-Gonda N, Igawa M, Shiina H, and Wada Y (1998) Heat-induced membrane damage combined with adriamycin on prostate carcinoma PC-3 cells: Correlation of cytotoxicity, permeability and P-glycoprotein or metallothionein expression. Br J Urol 82:552-559.
32. Oldberg A, Franzén A, and Heinegård D (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 83:8819-8823. (Pubitemid 17223492)
33. Raguz S and Yagüe E (2008) Resistance to chemotherapy: New treatments and novel insights into an old problem. Br J Cancer 99:387-391.
34. Ramankulov A, Lein M, Kristiansen G, Loening SA, and Jung K (2007) Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67:330-340.
35. Sánchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C, and Castellón EA (2009) Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 69: 1448-1459.
36. Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, and Tenen DG (1988) Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Res 48:5770-5774.
37. Shannon AM, Bouchier-Hayes DJ, Condron CM, and Toomey D (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29:297-307. (Pubitemid 37069660)
38. Sharom FJ (2008) ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9:105-127. (Pubitemid 351560534)
39. Sodek J, Ganss B, and McKee MD (2000) Osteopontin. Crit Rev Oral Biol Med 11: 279-303.
40. Spoelstra EC, Dekker H, Schuurhuis GJ, Broxterman HJ, and Lankelma J (1991) Pglycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines: Evidence for a saturation of active daunorubicin transport. Biochem Pharmacol 41:349-359.
41. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, and Riddick AC (2010) The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 105:8-13.
42. Vaupel P, Kelleher DK, and Höckel M (2001) Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28(2, Suppl 8)29-35. (Pubitemid 32522235)
43. Wai PY and Kuo PC (2004) The role of osteopontin in tumor metastasis. J Surg Res 121:228-241. (Pubitemid 39387464)
44. Wang KX and Denhardt DT (2008) Osteopontin: Role in immune regulation and stress responses. Cytokine Growth Factor Rev 19:333-345.
45. Weilbaecher KN, Guise TA, and McCauley LK (2011) Cancer to bone: A fatal attraction. Nat Rev Cancer 11:411-425.
46. Wilson WR and Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11:393-410.
47. Wu CP, Calcagno AM, and Ambudkar SV (2008) Reversal of ABC drug transportermediated multidrug resistance in cancer cells: Evaluation of current strategies. Curr Mol Pharmacol 1:93-105.
48. Zheng DQ, Woodard AS, Tallini G, and Languino LR (2000) Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem 275:24565-24574. (Pubitemid 30626553)